- Home
- AMCX vs ALDX Comparison
AMCX vs ALDX Comparison
Compare AMCX & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMCX
- ALDX
- Stock Information
- Founded
- AMCX 1980
- ALDX 2004
- Country
- AMCX United States
- ALDX United States
- Employees
- AMCX N/A
- ALDX N/A
- Industry
- AMCX Cable & Other Pay Television Services
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- AMCX Telecommunications
- ALDX Health Care
- Exchange
- AMCX Nasdaq
- ALDX Nasdaq
- Market Cap
- AMCX 316.7M
- ALDX 313.4M
- IPO Year
- AMCX 2011
- ALDX 2014
- Fundamental
- Price
- AMCX $7.65
- ALDX $5.20
- Analyst Decision
- AMCX Sell
- ALDX Strong Buy
- Analyst Count
- AMCX 5
- ALDX 2
- Target Price
- AMCX $6.50
- ALDX $9.50
- AVG Volume (30 Days)
- AMCX 399.1K
- ALDX 626.7K
- Earning Date
- AMCX 11-07-2025
- ALDX 11-06-2025
- Dividend Yield
- AMCX N/A
- ALDX N/A
- EPS Growth
- AMCX N/A
- ALDX N/A
- EPS
- AMCX N/A
- ALDX N/A
- Revenue
- AMCX $2,354,176,000.00
- ALDX N/A
- Revenue This Year
- AMCX N/A
- ALDX N/A
- Revenue Next Year
- AMCX N/A
- ALDX $36.23
- P/E Ratio
- AMCX N/A
- ALDX N/A
- Revenue Growth
- AMCX N/A
- ALDX N/A
- 52 Week Low
- AMCX $5.41
- ALDX $1.14
- 52 Week High
- AMCX $10.60
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- AMCX 51.19
- ALDX 46.47
- Support Level
- AMCX $7.05
- ALDX $5.06
- Resistance Level
- AMCX $7.88
- ALDX $5.55
- Average True Range (ATR)
- AMCX 0.30
- ALDX 0.29
- MACD
- AMCX -0.04
- ALDX -0.02
- Stochastic Oscillator
- AMCX 56.39
- ALDX 21.23
About AMCX AMC Networks Inc.
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.